Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20

Bristol Myers Squibb rolled out authorized generics (AGs) of its blood cancer drug Revlimid (lenalidomide) through its subsidiary on December 8 upon the reimbursement listing. Sawai Pharmaceutical also released its versions of the drug the same day. The roster of...read more